Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$565.2MCash on Hand
94.3mo Cash Runway
Follow SEPN by emailGet an email when SEPN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SEPN, unsubscribe in one click. Privacy
📣 What SEPN Says Is Next
first quarter of 2027 · “Additional details are available in the data release . o Following the successful completion of the remaining preclinical development activities, Septerna anticipates initiating a Phase 1 clinical trial for SEP-204 in healthy volunteers in the first quarter of 2027.”
Company press release, Nov 9, 2026 · SEC filing
first quarter of 2027 · SEP-479: “SEP-479 PTH1R Agonist for Hypoparathyroidism: o Septerna’s Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial of SEP-479, an oral small molecule PTH1R agonist in development for hypoparathyroidism, is ongoing in healthy volunteers, with data expected in the first quarter of 2027.”
Company press release, Nov 9, 2026 · SEC filing
Q1 2027 · “Multi-product pipeline, each with a multi- data in Q12027 Agonist billion $ market opportunity SEP-204 (TSHR) Anticipate Phase 1 initiation in Q1 2027 ® Negative Allosteric Modulator”
Company press release, Nov 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Earnings Reported Q3 2026 results: revenue of $18.9 million versus $21.5 million a year earlier, R&D expenses of $36.6 million, G&A of $9.6 million, and a net loss of $26.6 million. Cash totaled $565.2 million, funding operations at least into mid-2029. SEP-479 Phase 1 data expected Q1 2027. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 4, 2026 ·
Clinical trial Septerna selected SEP-204, an oral TSHR negative allosteric modulator, as its development candidate for Graves' disease and thyroid eye disease, and reported preclinical data ahead of a November 5 poster at the 2026 ATA meeting. A Phase 1 trial in healthy volunteers is planned to start in the first quarter of 2027. Form 8-K · SEC filing · Press release
Aug 25, 2026 ·
Leadership Septerna appointed Rajiv Patni, M.D., as Chief Medical Officer, effective August 24, 2026. Dr. Patni previously served as CEO of Judo Bio and Chief Research and Development Officer at Reata Pharmaceuticals. Form 8-K · SEC filing · Press release
Aug 10, 2026 ·
Earnings Septerna reported Q2 2026 results: cash of $516.5 million, expected to fund operations at least into 2029. Revenue was $26.7 million from the Novo Nordisk collaboration, against $0.1 million a year earlier. Net loss narrowed to $13.0 million from $24.8 million. The SEP-479 Phase 1 SAD/MAD data is expected in Q1 2027. Form 8-K · SEC filing · Press release
Aug 10, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Feb 2027 · Phase 1 · Recruiting · A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
SEPN holds $565.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $18M/quarter from operations,
an estimated runway of 94.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:10 · Low
Cash runway 94 months
ATM program on file since Mar 2026 +15
Shelf registration (S-3ASR, Mar 2026) +10
Company says cash lasts into mid-2029 -15We believe our cash, cash equivalents, and marketable securities of $565.2 million as of September 30, 2026 will be sufficient to fund our operations and capital expenditure requirements at least into mid-2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Mar 10, 2026 · Shelf registration with ATM program, up to $150M · S-3ASR
Oct 25, 2024 · Underwritten offering, $288M · 424B4
Share count 47,549,223 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SEPN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SEPN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.